DOCSLIB.ORG

Nitrile SKIN2 DECOUVREZ VOTRE 2Ième PEAU

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

NITRILE SKIN2 DECOUVREZ VOTRE 2IÈME PEAU PROTECTION CONTRE LES INFECTIONS – imperméable aux virus pour l’utilisateur et le patient EXCELLENTE SENSIBILITE TACTILE – grâce à une épaisseur optimisée PORT TRES CONFORTABLE – grâce au matériau souple novateur tre les on inf t très c c e or on n nte sen c P fo e si ti xemp r io ll b o E t d t t e il n e a c c i b t s l x é e a l e t E t t e o a x r c t n P i l a e t u r e l nitrile skin 2 EXAMINATION GLOVES BY SEMPERMED INFORMATION PRODUITS PROTECTION GANTS 8/3/2012 8/3/2012 RecommandationsRecommandations à propos de la résistance à proposINFORMATIONS aux de la résistance Sempermed® aux produits chimiquesproduits chimiques «Manipulation de produits chimiques en milieu hospitalier avec les gants nitrile Sempercare® 08/03/2012 Les gants de protection àLes usage gants unique de protectionSempercare® à usageont uniqueété contrôlés Sempercare® ont été contrôlés conformémentRecommandations aux exigences à propos deconformément la denorme la résistance EN aux 374-3 exigences aux « produits détermination de chimiques la norme de laEN résistance 374-3 « détermination de la résistance à la perméationLes gants par de desprotection produits àà usage la chimiques perméation unique Sempercare®». par des produits ont été contrôlés chimiques conformément ». aux exigences de la norme EN 374-3 « détermination de la résistance à la perméation par des produits chimiques ». Sempercare® Sempercare® Sempercare® Sempercare® Produit chimique Sempercare®Produit chimique Sempercare® Sempercare® Sempercare® Latex sans Nitrile sans Latex sans2 Nitrile sans 2 (synonymes) Latex poudré(synonymes) Latex poudré Nitrile Skin Nitrile Skin poudre poudre poudre poudre Acétone Acétone (2-propanone, cétopropane) (2-propanone,x cétopropane)x x x x x Acétonitrile Acétonitrile (cyanure de méthyle, éthanenitrile) (cyanurex de méthyle, éthanenitrile)x x x x x Acrylamide (40 %) Acrylamide (40 %) (amine d’acide acrylique) (amineNiveau d’acide 6 acrylique)Niveau 6 Niveau 6 Niveau 6 Niveau 6 Niveau 6 Ammoniaque (25 %) (hydroxyde Ammoniaque (25 %) (hydroxyde d’ammonium, alcali volatil) d’ammonium,A alcali volatil)A A A A Chlorure de benzalkonium liq. Chlorure de benzalkonium liq. (ammonium quaternaire, quat) (ammonium quaternaire,Niveau quat) 6 Niveau 6 Essence (lourde, p.é.150 - 190° - Essence (lourde, p.é.150 - 190° - CAS 8032-32-4) CAS 8032-32-4)x A Niveaux 1 Ax Niveau 1 x Chlorhexidine gluconate + éthanol Chlorhexidine gluconate + éthanol + eau + eau Niveau 1 Niveau 1 Chloroforme Chloroforme (trichlorométhane) (trichlorométhane)x x x x x x Cyclohexanol Cyclohexanol (hexaline / à 23°C) (hexaline / à 23°C) Niveau 1 Niveau 3 Niveau 1 Niveau 3 Dichlorométhane Dichlorométhane (chlorure de méthylène, fréon 30) (chlorurex de méthylène, fréonx 30) x x x x Diéthylamine Diéthylamine (DEA) (DEA) x x x x x x Éther diéthylique Éther diéthylique (oxyde de diéthyle, éthoxyéthane) (oxyde dex diéthyle, éthoxyéthane)x x x x x Diméthylsulfoxyde DMSO Diméthylsulfoxyde DMSO (méthylsulfinylméthane) (méthylsulfinylméthane)x x x x x x Acide acétique (10 %) Acide acétique (10 %) (acide acétylique, acide (acideNiveau acétylique, 6 acideNiveau 6 Niveau 6 Niveau 6 Niveau 6 Niveau 6 éthanoïque) éthanoïque) Éthanol (20 %) Éthanol (20 %) (alcool éthylique, méthylcarbinol) (alcool éthylique,A méthylcarbinol)A NiveauA 1 NiveauA 1 Niveau 1 Niveau 1 1800 Route des bleuets 1 / 3 Le Mirlibut - 76430 Etainhus 1 / 3 Tél. : +33 (0)2 35 44 93 93 - Fax : +33 (0)2 35 44 93 88 Site : www.groupe-didactic.fr V5-04/2012 Sempercare® Sempercare® Sempercare® Sempercare® Produit chimique Sempercare®Produit chimique Sempercare® Sempercare® Sempercare® Latex sans Nitrile sans Latex sans2 Nitrile sans 2 (synonymes) Latex poudré(synonymes) Latex poudré Nitrile Skin Nitrile Skin poudre poudre poudre poudre Éthanol (40 %) Éthanol (40 %) (alcool éthylique, méthylcarbinol) (alcool éthylique,x méthylcarbinol)x Ax Ax A A Éthanol (70 %) (alcool éthylique, Éthanol (70 %) (alcool éthylique, méthylcarbinol) méthylcarbinol)x x Ax Ax A A Éthanol (80 %) Éthanol (80 %) (alcool éthylique, méthylcarbinol) (alcool éthylique,x méthylcarbinol)x Ax Ax A A Éthanol p. A. Éthanol p. A. (alcool éthylique, méthylcarbinol) (alcool éthylique,x méthylcarbinol)x Ax x A x Bromure d’éthidium (1 %) Bromure d’éthidium (1 %) (bromure d’homidium) (bromurex d’homidium) x Niveaux 6 Niveaux 6 Niveau 6 Niveau 6 Acétate d’éthyle Acétate d’éthyle (ester éthylique de l'acide acétique, (ester éthyliquex de l'acide acétique,x Ax x A x étheracétique) étheracétique) Acide fluorhydrique (40 %) Acide fluorhydrique (40 %) (fluorure d’hydrogène) (fluorure d’hydrogène) A A Formaldéhyde (37 %) Formaldéhyde (37 %) (formol, aldéhyde formique) (formol, Aaldéhyde formique)Niveau 1 NiveauA 3 Niveau 12 Niveau 3 Niveau 2 Glutaraldéhyde (5 %) Glutaraldéhyde (5 %) (pentane-1,5-dial, glutaral) (pentane-1,5-dial, glutaral)Niveau 6 Niveau 6 Niveau 6 Niveau 6 Niveau 6 Alcool isopropylique (40 %) Alcool isopropylique (40 %) (2-propanol, isopropanol, IPA) (2-propanol,A isopropanol, IPA)A NiveauA 2 NiveauA 1 Niveau 2 Niveau 1 Alcool isopropylique (70 %) Alcool isopropylique (70 %) (2-propanol, isopropanol, IPA) (2-propanol,A isopropanol, IPA)A NiveauA 2 NiveauA 1 Niveau 2 Niveau 1 Alcool isopropylique p. a. Alcool isopropylique p. a. (2-propanol, isopropanol, IPA) (2-propanol,x isopropanol, IPA)A Niveaux 2 A Niveau 2 A Hydroxyde de potassium (30 %) Hydroxyde de potassium (30 %) (potasse caustique, lessive de (potasse caustique, lessiveNiveau de 1 Niveau 6 Niveau 16 Niveau 6 Niveau 6 potasse) potasse) Huile de lin Huile de lin A A A A A A Méthanol (5 %) Méthanol (5 %) (alcool méthylique, carbinol) (alcool méthylique, carbinol) Niveau 6 Niveau 6 Méthanol p. A. Méthanol p. A. (alcool méthylique, carbinol) (alcool méthylique,x carbinol)x Ax x A x Hydroxyde de sodium (30 %) Hydroxyde de sodium (30 %) (soude caustique, lessive de (soudeNiveau caustique, 6 lessiveNiveau de 6 Niveau 6 Niveau 6 Niveau 6 Niveau 6 soude) soude) Hydroxyde de sodium (40 %) Hydroxyde de sodium (40 %) (soude caustique, lessive de (soudeNiveau caustique, 6 lessiveNiveau de 6 Niveau 6 Niveau 6 Niveau 6 Niveau 6 soude) soude) N-heptane N-heptane (CAS 142-82-5) (CAS 142-82-5)x x Ax x A x N-hexane N-hexane (CAS 110-54-3) (CAS 110-54-3)x x Ax Ax A A Phénol (10 %) Phénol (10 %) (acide carbolique, (acide carbolique,A A A A hydroxybenzène) hydroxybenzène) Acide phosphorique (30 %) (acide Acide phosphorique (30 %) (acide orthophosphorique) orthophosphorique) Niveau 6 Niveau 6 2 / 3 2 / 3 1800 Route des bleuets Le Mirlibut - 76430 Etainhus Tél. : +33 (0)2 35 44 93 93 - Fax : +33 (0)2 35 44 93 88 Site : www.groupe-didactic.fr V5-04/2012 Sempercare® Sempercare® Produit chimique Sempercare® Sempercare® Latex sans Nitrile sans 2 (synonymes) Latex poudré Nitrile Skin poudre poudre Acide nitrique (10 %) Niveau 6 Niveau 6 Niveau 6 Niveau 6 Sempercare® Sempercare® Sempercare® Sempercare® Produit chimique Sempercare®Produit chimique Sempercare® Sempercare® Sempercare® Latex sans Nitrile sans Latex sans2 Nitrile sans 2 (synonymes)Acide nitrique (36 %)Latex poudré(synonymes) Latex poudré Nitrile Skin Nitrile Skin poudre poudreNiveau 6poudre poudre Niveau 6 Acide nitrique (10 %) Acide nitrique (10 %) Acide nitrique (50 %)Niveau 6 Niveau 6 Niveau 6 Niveau 6 Niveau 6 Niveau 6 Acide nitrique (36 %) Acide nitrique (36 %) Niveau 2 Niveau 6 Niveau 6 Niveau 6 Acide chlorhydrique (36 %) (acide Acide nitrique (50muriatique) %) Acide nitrique (50 %) Niveau 2 Niveau 2 Niveau 1 Niveau 2 Niveau 2 Acide sulfurique (96 %) Acide chlorhydrique (36 %) (acide Acide chlorhydrique (36 %) (acide Niveau 1 A muriatique) (vitriol, sulfate d'hydrogène)muriatique) Niveau 2 Niveau 2 Niveau 12 Niveau 2 Niveau 1 Acide sulfurique (96Toluol %) Acide sulfurique (96 %) (vitriol, sulfate d'hydrogène)(méthylbenzène, (vitriol,toluène, sulfate d'hydrogène)Niveau 1 x A x Niveau 1 x A x Toluol phénylméthane) Toluol (méthylbenzène, Trichloroéthanetoluène, (méthylbenzène,x toluène, x x x x x phénylméthane) (méthylchloroforme,phénylméthane) trichlorure de x x x x Trichloroéthane vinyle) Trichloroéthane (méthylchloroforme,Xylol trichlorure de (méthylchloroforme,x trichlorurex de x x x x vinyle) vinyle) (diméthylbenzène, xylène) x x x x Xylol Xylol (diméthylbenzène, xylène) (diméthylbenzène,x xylène) x x x x x X non recommandé X non recommandé X non recommandé A recommandé pourA recommandé contact par projectionA pour recommandé contact seulement pourpar projection–contact changer par immédiatement projectionseulement seulement – changer – changer immédiatement immédiatement de gant après contactde gant après contactde gant après contact Niveau 1 recommandéNiveau pour 1 recommandé contactNiveau court 1 seulement pourrecommandé contact pour court contact seulement court seulement Niveau 2 recommandéNiveau pour 2 recommandé applicationsNiveau jusqu’à2 pourrecommandé 60applications min. pour applications jusqu’à 60 jusqu’à min. 60 min. Niveau 3 recommandéNiveau pour 3 recommandé applicationsNiveau jusqu’à3 pourrecommandé 120applications min. pour applications jusqu’à 120 jusqu’à min. 120 min. Niveau 4 recommandéNiveau pour 4 recommandé applicationsNiveau jusqu’à4 pourrecommandé 240applications min. pour applications jusqu’à 240 jusqu’à min. 240 min. Niveau 5 recommandé pour applicationsNiveau jusqu’à5 recommandé 480 min. pour applications jusqu’à 480 min. Niveau 5 recommandé pour applications jusqu’à 480 min. Niveau 6 recommandé pour applicationsNiveau de6 recommandé plus de 480 min. pour applications de plus de 480 min. Niveau 6 recommandé
Recommended publications
  • Synthesis and Antitumor Evaluation of Novel Bis-Triaziquone Derivatives

    Synthesis and Antitumor Evaluation of Novel Bis-Triaziquone Derivatives

    Molecules 2009, 14, 2306-2316; doi:10.3390/molecules14072306 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Synthesis and Antitumor Evaluation of Novel Bis-Triaziquone Derivatives Cheng Hua Huang 1,3, Hsien-Shou Kuo 2, Jia-Wen Liu 3 and Yuh-Ling Lin 3,* 1 Cathay General Hospital, 280 Renai Rd. Sec.4, Taipei, Taiwan 2 Department of Biochemistry, Taipei Medical University, 250 Wu-Hsin St. Taipei, Taiwan 3 College of Medicine, Fu-Jen Catholic University, 510 Chung Cheng Rd., Hsin-Chuang, Taipei Hsien 24205, Taiwan * Author to whom correspondence should be addressed; E-mail: [email protected] Received: 30 April 2009; in revised form: 19 June 2009 / Accepted: 23 June 2009 / Published: 29 June 2009 Abstract: Aziridine-containing compounds have been of interest as anticancer agents since late 1970s. The design, synthesis and study of triaziquone (TZQ) analogues with the aim of obtaining compounds with enhanced efficacy and reduced toxicity are an ongoing research effort in our group. A series of bis-type TZQ derivatives has been prepared and their cytotoxic activities were investigated. The cytotoxicity of these bis-type TZQ derivatives were tested on three cancer lines, including breast cancer (BC-M1), oral cancer (OEC-M1), larynx epidermal cancer (Hep2) and one normal skin fibroblast (SF). Most of these synthetic derivatives displayed significant cytotoxic activities against human carcinoma cell lines, but weak activities against SF. Among tested analogues the bis-type TZQ derivative 1a showed lethal effects on larynx epidermal carcinoma cells (Hep2), with an LC50 value of 2.02 M, and also weak cytotoxic activity against SF cells with an LC50 value over 10 M for 24 hr treatment.
  • California Proposition 65 Toxicity List

    California Proposition 65 Toxicity List

    STATE OF CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986 CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY 4-Mar-05 The Safe Drinking Water and Toxic Enforcement Act of 1986 requires that the Governor revise and Chemical Type of Toxicity CAS No. Date Listed A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole) cancer 26148685 1-Jan-90 Acetaldehyde cancer 75070 1-Apr-88 Acetamide cancer 60355 1-Jan-90 Acetazolamide developmental 59665 20-Aug-99 Acetochlor cancer 34256821 1-Jan-89 Acetohydroxamic acid developmental 546883 1-Apr-90 2-Acetylaminofluorene cancer 53963 1-Jul-87 Acifluorfen cancer 62476599 1-Jan-90 Acrylamide cancer 79061 1-Jan-90 Acrylonitrile cancer 107131 1-Jul-87 Actinomycin D cancer 50760 1-Oct-89 Actinomycin D developmental 50760 1-Oct-92 Adriamycin (Doxorubicin hydrochloride) cancer 23214928 1-Jul-87 AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide cancer 3688537 1-Jul-87 Aflatoxins cancer --- 1-Jan-88 Alachlor cancer 15972608 1-Jan-89 Alcoholic beverages, when associated with alcohol abuse cancer --- 1-Jul-88 Aldrin cancer 309002 1-Jul-88 All-trans retinoic acid developmental 302794 1-Jan-89 Allyl chloride Delisted October 29, 1999 cancer 107051 1-Jan-90 Alprazolam developmental 28981977 1-Jul-90 Altretamine developmental, male 645056 20-Aug-99 Amantadine hydrochloride developmental 665667 27-Feb-01 Amikacin sulfate developmental 39831555 1-Jul-90 2-Aminoanthraquinone cancer 117793 1-Oct-89 p -Aminoazobenzene cancer
  • Human Cytogenetics Prenatal Diagnostics

    Human Cytogenetics Prenatal Diagnostics

    Cytogenetics Human Cytogenetics Prenatal Diagnostics Optimized Medium for Culture and Genetic Analysis of Human Amniotic Fluid Cells BIOAMF-1 and Chorionic Villi ( CV ) Samples Basal Medium and Supplement Chromosome Karyotyping was first developed in the BIOAMF-1 is designed for the primary culture of field of Cytogenetics. human amniotic fluid cells and chorionic villi (CV) The basic principle of the method is the preparation samples in both open (5% CO2) and closed systems. of chromosomes for microscopic observation by The medium allows rapid growth of amniocytes or arresting cell mitosis at metaphase with colchicine and treating the cells with a hypotonic solution. This chorionic villi for use in karyotyping. is followed by regular or fluorescent staining of the No supplementation with serum or serum- chromosomes, which are then tested with the aid of a substitutes is necessary. microscope and computer programs to arrange and The medium consists of two components: basal identify the chromosomes for the presence of genetic medium and frozen supplements. abnormalities. In principle, this method enables the identification Instructions for Use of any abnormality - excess chromosomes or For the preparation of 500ml complete medium, use chromosome deficiency, broken chromosomes, 01-190-1A with 01-192-1E. or excess genetic material (as a result of a For the preparation of 100ml complete medium, use recombination process). 01-190-1B with 01-192-1D. Clinical cytogenetics laboratories use this method Thaw the BIOAMF-1 Supplement by swirling in a with amniotic fluid, chorionic villi, blood cells, skin cells, and so on, which can be cell cultured to obtain 37ºC water bath, and transfer the contents to the mitotic cells.
  • The Chemotherapy of Malignant Disease -Practical and Experimental Considerations

    The Chemotherapy of Malignant Disease -Practical and Experimental Considerations

    Postgrad Med J: first published as 10.1136/pgmj.41.475.268 on 1 May 1965. Downloaded from POSTGRAD. MED. J. (1965), 41,268 THE CHEMOTHERAPY OF MALIGNANT DISEASE -PRACTICAL AND EXPERIMENTAL CONSIDERATIONS JOHN MATTHIAS, M.D., M.R.C.P., F.F.A., R.C.S. Physician, The Royal Marsden Hospital, London, S.W.3. THE TERM chemotherapy was introduced by positively charged alkyl (CH2) radicles of Ehrlich to describe the specific and effective the agent. treatment of infectious disease by chemical (a) The nitrogen mustards: mustine (HN2 substances. It is currently also applied to the 'nitrogen mustard', mechlorethamine, treatment of malignant disease. Unfortunately mustargen), trimustine (Trillekamin no aspect of tumour metabolism has been HN3), chlorambucil (Leukeran, phenyl discovered which has allowed the development butyric mustard), melphalan (Alkeran, of drugs capable of acting specifically upon the phenyl alanine mustard), uramustine malignant cell, so that cytotoxic drugs also (Uracil mustard), cyclophosphamide affect normal cells to a greater or lesser degree. (Endoxan or Cytoxan), mannomustine The most susceptible or sensitive of the normal (DegranoO). tissues are those with the highest rates of cell (b) The ethylenamines: tretamine (trie- turnover and include the haemopoietic and thanomelamine, triethylene melamine, lympho-reticular tissues, the gastro-intestinal TEM), thiotepa (triethylene thiopho- the the testis and the hair epithelium, ovary, sphoramide), triaziquone (Trenimon).by copyright. follicles. (c) The epoxides: triethyleneglycoldigly- Cancer chemotherapy may be said to encom- cidyl ether (Epodyl). pass all treatments of a chemical nature (d) The sulphonic acid esters: busulphan administered to patients with the purpose of (Myleran), mannitol myleran. restricting tumour growth or destroying tumour 2.
  • (12) United States Patent (10) Patent No.: US 8,999,632 B2 Falcon Et Al

    (12) United States Patent (10) Patent No.: US 8,999,632 B2 Falcon Et Al

    US008.999632B2 (12) United States Patent (10) Patent No.: US 8,999,632 B2 Falcon et al. (45) Date of Patent: Apr. 7, 2015 (54) METHOD FOR MEASURING ATR (52) U.S. Cl. INHIBITION MEDIATED INCREASES IN DNA CPC ............ G0IN33/5047 (2013.01); G0IN33/68 DAMAGE (2013.01) (58) Field of Classification Search (71) Applicants: Vertex Pharmaceuticals Incorporated, USPC ........................................................ 435/2, 15 Cambridge, MA (US); University of See application file for complete search history. Newcastle Upon Tyne, Newcastle Upon Tyne (GB) (56) References Cited (72) Inventors: Susanna Falcon, Newbury (GB); Philip PUBLICATIONS Reaper, Shillingford (GB); John Kao et al. Inhibition of Gamma-H2AXAfter Ionizing Radiation. As a Pollard, Abingdon (GB); Nicola Curtin, Biological Surrogate of Impaired Upstream DNA Damage Signaling Newcastle upon Tyne (GB); Fiona and Radiosensitivity; Journal of Cancer Molecules, vol. 5, No. 2 Middleton, South Gosforth (GB); Tao (2010) pp. 49-54.* Chen, Suzhou (CN) Buscemi, G., et al., “DNA Damage-Induced Cell Cycle Regulation of Novel Chk2 Phosphoresidues'. Molecular and Cellular Biology, (73) Assignee: Vertex Pharmaceuticals Incorporated, 26(21), (2006), pp. 7832-7845 (DOI: 10.1128/MCB.00534-06). Boston, MA (US) Chen, T., et al., “Targeting the S and G2 checkpoint to treat cancer. s Drug Discovery Today, 17(5/6), (2012), pp. 194-202, (DOI: 10.1016/ - r - j.drudis.2011, 12.009). (*) Notice: Subject to any disclaimer, the term of this Chen, T., et al., “Development of a biomarker of ATR activity in patent is extended or adjusted under 35 surrogate human tissues”, Newcastle University, Poster, Nov. 2012. U.S.C. 154(b) by 0 days.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance

    Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance

    cells Review Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance Ronay Cetin 1,† , Eva Quandt 2,† and Manuel Kaulich 1,3,4,* 1 Institute of Biochemistry II, Goethe University Frankfurt-Medical Faculty, University Hospital, 60590 Frankfurt am Main, Germany; [email protected] 2 Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195 Barcelona, Spain; [email protected] 3 Frankfurt Cancer Institute, 60596 Frankfurt am Main, Germany 4 Cardio-Pulmonary Institute, 60590 Frankfurt am Main, Germany * Correspondence: [email protected]; Tel.: +49-(0)-69-6301-5450 † These authors contributed equally to this work. Abstract: Drug resistance is a commonly unavoidable consequence of cancer treatment that results in therapy failure and disease relapse. Intrinsic (pre-existing) or acquired resistance mechanisms can be drug-specific or be applicable to multiple drugs, resulting in multidrug resistance. The presence of drug resistance is, however, tightly coupled to changes in cellular homeostasis, which can lead to resistance-coupled vulnerabilities. Unbiased gene perturbations through RNAi and CRISPR technologies are invaluable tools to establish genotype-to-phenotype relationships at the genome scale. Moreover, their application to cancer cell lines can uncover new vulnerabilities that are associated with resistance mechanisms. Here, we discuss targeted and unbiased RNAi and CRISPR efforts in the discovery of drug resistance mechanisms by focusing on first-in-line chemotherapy and their enforced vulnerabilities, and we present a view forward on which measures should be taken to accelerate their clinical translation. Citation: Cetin, R.; Quandt, E.; Kaulich, M. Functional Genomics Keywords: chemotherapy resistance; cancer and drug vulnerabilities; functional genomics; RNAi Approaches to Elucidate Vulnerabilities of Intrinsic and and CRISPR screens Acquired Chemotherapy Resistance.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • (12) United States Patent (10) Patent No.: US 8,580,267 B2 Pedretti Et Al

    (12) United States Patent (10) Patent No.: US 8,580,267 B2 Pedretti Et Al

    US008580267B2 (12) United States Patent (10) Patent No.: US 8,580,267 B2 Pedretti et al. (45) Date of Patent: Nov. 12, 2013 (54) IMMUNOCYTOKINES FORTUMOUR (56) References Cited THERAPY WITH CHEMOTHERAPEUTIC AGENTS FOREIGN PATENT DOCUMENTS (75) Inventors: Marta Pedretti, Zurich (CH): Dario WO O2/O59264 8, 2002 WO O3,O93478 11, 2003 Neri, Buchs (CH) WO 2004/OO2528 1, 2004 WO 2006/026020 3, 2006 (73) Assignee: Philogen S.p.A., Siena (IT) WO 2006/050834 5, 2006 WO 2007/128563 11, 2007 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Paul, William, Fundamental Immunology, 3rd Edition, Raven Press, New York, 1993, pp. 292-295.* (21) Appl. No.: 13/139,655 Vajdos et al., Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning 1-1. mutagenesis. J. Mol. Biol. 320:415-428, 2002.* (22) PCT Filed: Dec. 14, 2009 Bartolomei, M., et al. “Combined treatment of glioblastomapatients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and (86). PCT No.: PCT/EP2009/008920 temozolomide.” QJNuclMed Mol Imaging. Sep. 2004:48(3):220-8. S371 (c)(1) Marlind, J., et al. "Antibody-mediated delivery of interleukin-2 to the (2), (4) Date. Jun. 14, 2011 Stroma of breast cancer strongly enhances the potency of chemo s 9 therapy” Clin Cancer Res. Oct. 15, 2008;14(20):6515-24. Brack, S.S., et al. “Tumor-targeting properties of novel antibodies (87) PCT Pub. No.: WO2010/078916 specific to the large isoform oftenascin-C.” Clin Cancer Res.
  • Ep 2569287 B1

    Ep 2569287 B1

    (19) TZZ _T (11) EP 2 569 287 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 413/04 (2006.01) C07D 239/46 (2006.01) 09.07.2014 Bulletin 2014/28 (86) International application number: (21) Application number: 11731562.2 PCT/US2011/036245 (22) Date of filing: 12.05.2011 (87) International publication number: WO 2011/143425 (17.11.2011 Gazette 2011/46) (54) COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERBINDUNGEN ALS HEMMER DER ATR-KINASE COMPOSÉS UTILISABLES EN TANT QU’INHIBITEURS DE LA KINASE ATR (84) Designated Contracting States: • VIRANI, Aniza, Nizarali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abingdon GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Oxfordshire OX144RY (GB) PL PT RO RS SE SI SK SM TR • REAPER, Philip, Michael Abingdon (30) Priority: 12.05.2010 US 333869 P Oxfordshire OX144RY (GB) (43) Date of publication of application: (74) Representative: Coles, Andrea Birgit et al 20.03.2013 Bulletin 2013/12 Kilburn & Strode LLP 20 Red Lion Street (73) Proprietor: Vertex Pharmaceuticals Inc. London WC1R 4PJ (GB) Boston, MA 02210 (US) (56) References cited: (72) Inventors: WO-A1-2010/054398 WO-A1-2010/071837 • CHARRIER, Jean-Damien Abingdon • C. A. HALL-JACKSON: "ATR is a caffeine- Oxfordshire OX144RY (GB) sensitive, DNA-activated protein kinase with a • DURRANT, Steven, John substrate specificity distinct from DNA-PK", Abingdon ONCOGENE, vol. 18, 1999, pages 6707-6713, Oxfordshire OX144RY (GB) XP002665425, cited in the application • KNEGTEL, Ronald, Marcellus Alphonsus Abingdon Oxfordshire OX144RY (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
  • WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT

    WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT (51) International Patent Classification: achusetts 021 15 (US). THE BROAD INSTITUTE, A61K 51/10 (2006.01) G01N 33/574 (2006.01) INC. [US/US]; 415 Main Street, Cambridge, Massachu C07K 14/705 (2006.01) A61K 47/68 (2017.01) setts 02142 (US). MASSACHUSETTS INSTITUTE OF G01N 33/53 (2006.01) TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). (21) International Application Number: PCT/US2017/055625 (72) Inventors; and (71) Applicants: KUCHROO, Vijay K. [IN/US]; 30 Fairhaven (22) International Filing Date: Road, Newton, Massachusetts 02149 (US). ANDERSON, 06 October 2017 (06.10.2017) Ana Carrizosa [US/US]; 110 Cypress Street, Brookline, (25) Filing Language: English Massachusetts 02445 (US). MADI, Asaf [US/US]; c/o The Brigham and Women's Hospital, Inc., 75 Francis (26) Publication Language: English Street, Boston, Massachusetts 021 15 (US). CHIHARA, (30) Priority Data: Norio [US/US]; c/o The Brigham and Women's Hospital, 62/405,835 07 October 2016 (07.10.2016) US Inc., 75 Francis Street, Boston, Massachusetts 021 15 (US). REGEV, Aviv [US/US]; 15a Ellsworth Ave, Cambridge, (71) Applicants: THE BRIGHAM AND WOMEN'S HOSPI¬ Massachusetts 02139 (US). SINGER, Meromit [US/US]; TAL, INC. [US/US]; 75 Francis Street, Boston, Mass c/o The Broad Institute, Inc., 415 Main Street, Cambridge, (54) Title: MODULATION OF NOVEL IMMUNE CHECKPOINT TARGETS CD4 FIG.
  • (12) United States Patent (10) Patent No.: US 7,612,250 B2

    (12) United States Patent (10) Patent No.: US 7,612,250 B2

    US00761225OB2 (12) UnitedO States Patent (10) Patent No.: US 7,612,250 B2 Overstrom et al. (45) Date of Patent: Nov. 3, 2009 (54) NUCLEAR TRANSFER EMBRYO OTHER PUBLICATIONS FORMATION METHOD Ibanez et al. Biology of Reproduction, 2003, 68:1249-1258.* (75) Inventors: Eric W. Overstrom, Grafton, MA (US); Baguisi et al. Nature, May 1999, 17:456-461.* Daniela Fischer Russell, Guelph (CA) Lai. L. et al., “Feasibility of Producing Porcine Nuclear Transfer s Embryos by Using G2/M-Stage Fetal Fibroblasts as Donors.” Biol (73) Assignee: Trustees of Tufts College, Medford, MA ogy of Reproduction, 65:1558-1564 (2001). (US) Vogel, “Misguided Chromosomes Foil Primate Cloning.” Science, 300: 225 and 227 (2003). ( c ) Notice: Subj ect to any disclaimer, the term of this Simerly, Molecular Correlates of Primate Nuclear Transfer Fail atent is extended or adjusted under 35 ures,” et al., Science, 300: 297 (2003). p S.C. 154(b) by 103 days Zieve, et al., “Production of Large Numbers of Mitotic Mammalian M YW- y yS. Cells by Use of the Reversible Microtubule Inhibitor Nocodazole.” Exp. Cell Res., 126(2): 397-405 (1980). (21) Appl. No.: 10/208,653 Ibanez, E., et al., “Genetic Strain Variations in the Metaphase-II 1-1. Phenotype of Mouse Oocytes Matured in vivo or in vitro.” Repro (22) Filed: Jul. 29, 2002 duction, 130: 845-855 (2005). O O Gasparrin, B., et al., "Cloned Mice Derived from Embryonic Stem (65) Prior Publication Data Cell Karyoplasts and Activated Cytoplasts Prepared by Induced US 2004/OO19924 A1 Jan. 29, 2004 Enucleation.” Biology of Reproduction, 68: 1259-1266 (2003).